Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…
The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primarily effective in treating positive symptoms. However, in late 2019, the U.S…
More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has…
The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years…
Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…
Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or even aggression and can occur in both…
Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or even aggression and can occur in both…
Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…
Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunoglobulin…
Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunoglobulin…
Research on the human microbiome is expanding beyond C. difficile, with microbiome-based therapies reaching the clinical trial phase of development for additional disease areas. Investments in this…
Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…